BCL2 and acute myeloid leukemia: To understand the mechanisms underlying resistance to venetoclax in AML, one recent study utilized a genome-wide CRISPR/Cas9 screen (targeting 18,010 genes with ~5 sgRNA per gene) and identified the apoptotic network triggered by TP53 is required for the therapeutic response to BCL2 inhibition in AML [35].